Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient

Ann Oncol. 2016 Dec;27(12):2304-2305. doi: 10.1093/annonc/mdw293. Epub 2016 Aug 8.

Authors

B R Gastman^{1

2

3}, M S Ernstoff²

Affiliations

¹ Department of Plastic Surgery [email protected].
² Departments of Immunology, Cleveland Clinic Foundation, Cleveland.
³ Departments of Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, USA.

PMID: 27502714
DOI: 10.1093/annonc/mdw293

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Bone Neoplasms / diagnosis
Bone Neoplasms / drug therapy
Bone Neoplasms / immunology
Female
Genes, cdc / drug effects
Genes, cdc / immunology
Heart Transplantation* / trends
Humans
Ipilimumab / pharmacology
Ipilimumab / therapeutic use*
Liver Neoplasms / diagnosis
Liver Neoplasms / drug therapy
Liver Neoplasms / immunology
Melanoma / diagnosis
Melanoma / drug therapy
Melanoma / immunology
Transplant Recipients*

Substances

Antineoplastic Agents, Immunological
Ipilimumab